Contact person:
Vitaly Kocherbitov
  • Vinnova
  • Swedish Research Council
Responsible at MaU:
Vitaly Kocherbitov
Project members at MaU:
Collaborators :
  • RISE (Anna Fureby project leader)
  • Lund University
  • MAX IV
  • Uppsala University Hospital
  • Swedish Orphan Biovitrum AB
  • BioGaia AB
  • Regenics AS
  • Ilya Pharma AB
  • Spiber Technologies AB
  • Ferring Pharmaceuticals AB
  • Vironova AB
  • Solve Research and Consultancy AB
  • CR Competence AB
  • SARomics
  • ENZA Biotech
  • Sofus Regulatory Affairs AB
  • Biogardia AB
Time frame:
01 January 2018 - 01 January 2025

About the project

About one third of all new medicines that are produced are so-called biological medicines. The term includes various vaccines, antibodies against cancer, insulin for diabetics and growth hormone. Unlike traditional medicines, these are produced in biological systems, i.e. that the active substance comes from a living cell or tissue. Biological medicines are vital to many people with lifelong diseases such as diabetes. The problem is that biological medicines are often sensitive and difficult products and it is often hard to create stable formulations.

NextBioForm is a centre for competence development, innovation and development of formulations and process technologies for biologically based pharmaceuticals. In this project, industry and academia collaborate with the aim of creating knowledge and methods that are needed to develop medicines that are easier for the patient to use, and thereby improve quality of life.

The research within NextBioForm is focused on formulations and processing of biologics, specifically proteins and probiotic bacteria.

The research is divided into four work different work packages:

  • Stabilisation in liquid formulations
  • Innovative dry formulations
  • Novel strategies for local and targeted drug delivery
  • New characterization methods for biologics and drug formulations.